How I treat non-transfusion-dependent β-thalassemia
Saliba and colleagues use 4 illustrative cases to delineate diagnosis and treatment of non-transfusion-dependent β-thalassemia. The authors discuss their approa
Related Articles
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality
The novel EHA/EBMT grading of ICAHT closely reflects the extent of hematological toxicity following BCMA- and CD19-directed CAR-T therapy.Severe ICAHT was
Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients
Key Points. Obinutuzumab can safely be used in combination with chemotherapy and in maintenance after ASCT as frontline therapy in MCL patients.Obinutuzuma
The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy
Abstract. The routine use of next-generation sequencing methods has underscored the genetic and clonal heterogeneity of acute myeloid leukemia (AML), subsequent
The approach of HMA plus VEN with or without BMT for all patients with AML
Abstract. Treatment options for acute myeloid leukemia (AML) have expanded over the last 5 years. New regimens are increasing the options for patients who
Improving long-term outcomes with intensive induction chemotherapy for patients with AML
Abstract. Intensive chemotherapy in combination with allogeneic hematopoietic cell transplantation and supportive care can induce long-term remissions in a
High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention
Key Points. High-dose alemtuzumab led to effective suppression of chronic GVHD.Lymphodepletion delays Tn recovery resulting in lower TCR repertoire and hig
CAR T-cell Therapy in Mantle Cell Lymphoma with Secondary CNS Involvement – a multicenter experience.
Gulrayz Ahmed, Aseel Alsouqi, Aniko Szabo, Laura Samples, Mazyar Shadman, Farrukh T Awan, Alexandra E. Rojek, Peter A Riedell, Madiha Iqbal, Timothy S. Fen
Hidden treasures of histocompatibility
In this issue of Blood, Fuchs et al1 have used T-cell biology, coupled with Genome Wide Association Studies (GWAS) and computational leverage of public dat
Hidden treasures of histocompatibility
In this issue of Blood, Fuchs et al1 have used T-cell biology, coupled with Genome Wide Association Studies (GWAS) and computational leverage of public dat
Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy
Sonrotoclax is a potent and selective BCL2 inhibitor that is also effective in venetoclax-resistant BCL2 mutants both in vitro and in vivo.The crystal stru